This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engelbach, M. Articles by Beyer, J. Search for Related Content PubMed PubMed Citation Articles by Engelbach, M. Articles by Beyer, J.

Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements¹

Department of Internal Medicine and Endocrinology (M.E., T.F., A.P., R.D., S.H., T.K., J.B.), University Hospital of Mainz, 55101 Mainz, Germany; and Department of Nuclear Medicine (R.G., A.B.), University Hospital of Essen, 45122 Essen, Germany

Address correspondence and requests for reprints to: Martin Engelbach, M.D., Department of Internal Medicine and Endocrinology, 55101 Mainz, Germany. E-mail: engelbac{at}mail.uni-mainz.de

Calcitonin (CT) is an important tumor marker for medullary thyroid carcinoma (MTC). Recent CT assays chiefly recognize the monomeric form of CT (mCT). It was the objective of this study to examine the consequences of the higher specificity of the assay for interpretation of the postoperative CT values in MTC patients.

The postoperative mCT concentration was measured in 214 patients with differentiated thyroid carcinoma (MTC excepted; non-MTC patients) to determine a reference range of mCT in totally thyroidectomized patients. Monomeric CT was also determined with a two-site chemiluminescence immunoassay (Nichols) in 94 healthy subjects and in 68 MTC patients. The mCT concentrations were below the detection limit in all examined completely thyroidectomized non-MTC patients. Basal and stimulated mCT values were also below the detection limit in 32 of the 68 MTC patients. The biochemical and imaging diagnosis of the latter patients did not give any indication of tumor recurrence.

We conclude that completely thyroidectomized patients with non-MTC do not show any measurable mCT concentrations. In comparison with an unspecific CT-RIA, the more specific mCT determination by immunoluminometric assay permits a more precise differentiation between postoperative normal and pathological values and an earlier diagnosis of recurrent MTC.

This article has been cited by other articles:

				M. d'Herbomez, P. Caron, C. Bauters, C. Do Cao, J.-L. Schlienger, R. Sapin, L. Baldet, B. Carnaille, J.-L. Wemeau, and the French Group GTE (Groupe des Tumeurs Endocrine Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking Eur. J. Endocrinol., December 1, 2007; 157(6): 749 - 755. [Abstract] [Full Text] [PDF]

				F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H. R. Macke, J. Muller-Brand, and M. A. Walter Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial Clin. Cancer Res., November 15, 2007; 13(22): 6696 - 6702. [Abstract] [Full Text] [PDF]

				I. Borget, G. De Pouvourville, and M. Schlumberger Calcitonin Determination in Patients with Nodular Thyroid Disease J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 425 - 427. [Full Text] [PDF]

				R. Elisei, B. Cosci, C. Romei, V. Bottici, M. Sculli, R. Lari, R. Barale, F. Pacini, and A. Pinchera RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3579 - 3584. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				V. Quidville, N. Segond, E. Pidoux, R. Cohen, A. Jullienne, and S. Lausson Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase Endocrinology, May 1, 2004; 145(5): 2561 - 2571. [Abstract] [Full Text] [PDF]